866-997-4948(US-Canada Toll Free)

Bone Metastasis - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 137 Pages


Global Markets Directs, \'Bone Metastasis Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bone Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Metastasis. 

Bone Metastasis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Bone Metastasis.
  • A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Bone Metastasis pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Bone Metastasis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 6
Global Markets Direct Report Coverage 6
Bone Metastasis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Bone Metastasis 8
Bone Metastasis Therapeutics under Development by Companies 10
Bone Metastasis Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Bone Metastasis Therapeutics - Products under Development by Companies 17
Bone Metastasis Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Bone Metastasis Therapeutics Development 19
Celsion Corporation 19
Amgen Inc. 20
Cephalon, Inc. 21
Teva Pharmaceutical Industries Limited 22
Exelixis, Inc. 23
Bayer AG 24
Medivir AB 25
Osteologix, Inc. 26
Green Cross Corporation 27
Merrion Pharmaceuticals Plc 28
Digna Biotech, S.L. 29
Debiopharm Group 30
Amura Holdings Ltd. 31
Alethia Biotherapeutics Inc. 32
Deciphera Pharmaceuticals, LLC 33
Targa Therapeutics Corp. 34
Bone Metastasis - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
denosumab - Drug Profile 41
denosumab - Drug Profile 44
ART-010 - Drug Profile 47
Debio-0719 - Drug Profile 48
P-17 - Drug Profile 49
disitertide - Drug Profile 51
cabozantinib - Drug Profile 53
doxorubicin - Drug Profile 55
radium Ra 223 dichloride - Drug Profile 57
radium Ra 223 dichloride - Drug Profile 59
MIV-711 - Drug Profile 61
Docetaxel + Gleevec - Drug Profile 62
zoledronic acid - Drug Profile 64
BMTP-11 - Drug Profile 66
zoledronic acid - Drug Profile 67
MLN-1202 - Drug Profile 68
Alpharadin + [docetaxel] - Drug Profile 69
zoledronic acid + [cisplatin] + [docetaxel] - Drug Profile 71
CEP-37251 - Drug Profile 72
everolimus - Drug Profile 73
AB-25E9 - Drug Profile 74
AM-3701 - Drug Profile 75
VEGF/rGel - Drug Profile 76
Docetaxel + Carboplatin + Trastuzumab + Bevacizumab - Drug Profile 78
MG-1102 - Drug Profile 80
DCC-2909 - Drug Profile 81
AC-301 - Drug Profile 82
Secreted Phosphoprotein 24 KDa - Drug Profile 83
Bone Metastasis Therapeutics - Drug Profile Updates 84
Bone Metastasis Therapeutics - Discontinued Products 122
Bone Metastasis Therapeutics - Dormant Products 123
Bone Metastasis - Product Development Milestones 125
Featured News & Press Releases 125

Appendix 134
Methodology 134
Coverage 134
Secondary Research 134
Primary Research 134
Expert Panel Validation 134
Contact Us 135
Disclaimer 135

List of Table


Number of Products Under Development for Bone Metastasis, H1 2013 10
Products under Development for Bone Metastasis - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Investigation by Universities/Institutes, H1 2013 14
Comparative Analysis by Late Stage Development, H1 2013 15
Comparative Analysis by Mid Clinical Stage Development, H1 2013 16
Comparative Analysis by Early Clinical Stage Development, H1 2013 17
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Investigation by Universities/Institutes, H1 2013 20
Celsion Corporation, H1 2013 21
Amgen Inc., H1 2013 22
Cephalon, Inc., H1 2013 23
Teva Pharmaceutical Industries Limited, H1 2013 24
Exelixis, Inc., H1 2013 25
Bayer AG, H1 2013 26
Medivir AB, H1 2013 27
Osteologix, Inc., H1 2013 28
Green Cross Corporation, H1 2013 29
Merrion Pharmaceuticals Plc, H1 2013 30
Digna Biotech, S.L., H1 2013 31
Debiopharm Group, H1 2013 32
Amura Holdings Ltd., H1 2013 33
Alethia Biotherapeutics Inc., H1 2013 34
Deciphera Pharmaceuticals, LLC, H1 2013 35
Targa Therapeutics Corp., H1 2013 36
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Stage and Molecule Type, H1 2013 42
Bone Metastasis Therapeutics - Drug Profile Updates 86
Bone Metastasis Therapeutics - Discontinued Products 124
Bone Metastasis Therapeutics - Dormant Products 125
Bone Metastasis Therapeutics - Dormant Products (Contd..1) 126

List of Chart


Number of Products under Development for Bone Metastasis, H1 2013 10
Products under Development for Bone Metastasis - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 14
Late Stage Products, H1 2013 15
Mid Clinical Stage Products, H1 2013 16
Early Clinical Stage Products, H1 2013 17
Pre-Clinical Stage Products, H1 2013 18
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Route of Administration, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Molecule Type, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *